While IBM’s latest financial results and strategic moves paint a picture of a company in transition, its stock price tells a different story. Investor concerns appear centered on competitive threats from the AI sector, overshadowing what was a record-setting period for the technology giant.
Financial Strength Meets Market Weakness
The company closed its fourth quarter of 2025 with powerful results. Revenue climbed 12% to $19.7 billion, fueled by a 14% surge in software sales and a 21% jump in infrastructure. Earnings per share reached $4.52, comfortably surpassing the $4.31 consensus estimate from analysts. For the full year, IBM generated $14.7 billion in free cash flow, marking a $2 billion increase from the prior year.
Looking ahead to 2026, management is targeting revenue growth exceeding 5% and an approximate $1 billion expansion in free cash flow. The cumulative booked value for generative AI engagements has now crossed the $12.5 billion threshold. Despite these metrics, the equity trades roughly 20% below its 52-week peak and remains beneath its key moving averages.
Assessing the Competitive Landscape
A significant catalyst for the recent share price decline was news from AI startup Anthropic, which announced capabilities in modernizing COBOL code—a core domain long dominated by IBM. Legacy system revenue remains substantial; mainframe hardware constituted about 23% of IBM’s 2025 sales, with associated software contributing another 29% of total software revenue.
IBM has been quick to respond, noting that its own WatsonX Code Assistant tool has performed this specific task for two years. Furthermore, the company’s business mix has evolved. Its software segment, now accounting for around 45% of total business, grew 9% in 2025—its highest annual growth rate on record. Within this segment, Data and Automation units posted fourth-quarter gains of 19% and 14%, respectively.
Strategic Moves and Board Refresh
Concurrent with its earnings report, IBM secured a $112 million contract with the U.S. Department of Defense to modernize pricing systems in military commissaries. A separate partnership with Deepgram will integrate the latter’s speech AI technology into the watsonx platform, bolstering IBM’s enterprise AI offerings.
Should investors sell immediately? Or is it worth buying IBM?
On March 6, the company launched its new FlashSystem portfolio, boasting up to 40% greater data efficiency and ransomware detection in under 60 seconds. The planned acquisition of Confluent for $31 per share is expected to finalize by mid-2026, enhancing IBM’s hybrid cloud capabilities.
In a governance update, IBM expanded its board in early March with the appointment of Ramon Laguarta, Chairman and CEO of PepsiCo, who brings extensive experience in digital transformation. A concurrently filed charter amendment aims to strengthen shareholder rights.
The Quantum Computing Frontier
A potentially transformative element in IBM’s portfolio is its leadership in quantum computing. In early March, an international research team involving IBM scientists published a discovery in the journal Science: a novel molecule characterized using quantum computers. This milestone serves as tangible proof of the technology’s practical applicability.
Should quantum computing realize its potential, this division could not only offset but significantly surpass revenue from legacy mainframe operations. The consulting division’s backlog stands at $32 billion, with over a quarter related to generative AI.
Path Forward for Investors
Shareholders will receive a quarterly dividend of $1.68 per share on March 10. The company’s debt level has risen to $66 billion, approximately 45% of total assets, largely due to acquisition activity. Whether the stock can stage a recovery hinges on IBM’s ability to convincingly translate its investments in AI and cloud into sustained growth—and on the market’s recognition that the company is far more than a legacy hardware provider.
Ad
IBM Stock: Buy or Sell?! New IBM Analysis from March 9 delivers the answer:
The latest IBM figures speak for themselves: Urgent action needed for IBM investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 9.
IBM: Buy or sell? Read more here...
